Carta Healthcare, a leading provider of AI-powered clinical data abstraction, today announced it has secured $18.25 million in Series B1 financing. This investment will accelerate the company's ...

Through its industry-leading, AI-driven technology, Carta Healthcare supports the healthcare data registry market by transforming the previously manual clinical data abstraction process.

In data evaluated from clinical studies to date, ivospemin has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events.